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Introduction: Diarrheal disease is a leading cause of child mortality globally, and rotavirus is responsible
for more than a third of those deaths. Despite substantial decreases, the number of rotavirus deaths in
children under five was 215,000 per year in 2013. Of these deaths, approximately 41% occurred in Asia
and 3% of those in Bangladesh. While Bangladesh has yet to introduce rotavirus vaccination, the country
applied for Gavi support and plans to introduce it in 2018. This analysis evaluates the impact and cost-
effectiveness of rotavirus vaccination in Bangladesh and provides estimates of the costs of the vaccination
program to help inform decision-makers and international partners.
Methods: This analysis used Pan American Health Organization’s TRIVAC model (version 2.0) to examine
nationwide introduction of two-dose rotavirus vaccination in 2017, compared to no vaccination. Three
mortality scenarios (low, high, and midpoint) were assessed. Benefits and costs were examined from
the societal perspective over ten successive birth cohorts with a 3% discount rate. Model inputs were
locally acquired and complemented by internationally validated estimates.
Results: Over ten years, rotavirus vaccination would prevent 4000 deaths, nearly 500,000 hospitalizations
and 3 million outpatient visits in the base scenario. With a Gavi subsidy, cost/disability adjusted life year
(DALY) ratios ranged from $58/DALY to $142/DALY averted. Without a Gavi subsidy and a vaccine price of
$2.19 per dose, cost/DALY ratios ranged from $615/DALY to $1514/DALY averted.
Conclusion: The discounted cost per DALY averted was less than the GDP per capita for nearly all scenar-
ios considered, indicating that a routine rotavirus vaccination program is highly likely to be cost-effective.
Even in a low mortality setting with no Gavi subsidy, rotavirus vaccination would be cost-effective. These
estimates exclude the herd immunity benefits of vaccination, so represent a conservative estimate of the
cost-effectiveness of rotavirus vaccination in Bangladesh.
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Diarrheal disease is one of the leading causes of child mortality
globally, and rotavirus is responsible for more than a third of those
deaths [1–3]. While there is some variation in global mortality esti-
mates by source, rotavirus mortality has fallen dramatically over
the past two decades. In 2000, the number of deaths due to rota-
virus disease was estimated to be 518,000 per year in children
under five years of age. In 2013, this number decreased to
215,000 rotavirus deaths per year in children under five years of
age. Of these deaths, 121,000 occurred in Sub-Saharan Africa and
89,000 occurred in Asia. As many as 2700 of these deaths are esti-
mated to occur in Bangladesh [2,4]. While deaths are an important
component of rotavirus burden, there are additional health and
economic consequences due to rotavirus disease.
Currently, there are twoWorld Health Organization (WHO) pre-
qualified rotavirus vaccines available globally to help reduce the
burden of rotavirus disease. These two vaccines are Rotarix
(manufactured by GlaxoSmithKline), administered as a two-dose
schedule, and RotaTeq (manufactured by Merck & Co., Inc.),
administered as a three-dose schedule. According to WHO recom-
mendations, rotavirus vaccines should be introduced into every
country’s national immunization program, particularly those
where diarrhea is a leading cause of child death. Consistent with
this recommendation, more than 80 countries have introduced
http://dx.doi.org/10.1016/j.vaccine.2017.05.087
0264-410X/ 2017 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding author.
E-mail address: cpecenka@path.org (C. Pecenka).
Vaccine 35 (2017) 3982–3987
Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vaccine
rotavirus vaccination [5]. Gavi, the Vaccine Alliance also supports
rotavirus vaccination by subsidizing the cost of vaccination in eli-
gible countries [6]. Despite the WHO recommendation, Gavi sup-
port and large declines in global mortality, substantial mortality,
morbidity, and economic burden due to rotavirus disease remain
[7].
Bangladesh has played a leading role in building the evidence
base for rotavirus vaccination, as well as other interventions to
combat diarrheal disease (i.e., oral rehydration salts) [8,9]. In
2016, Bangladesh applied for Gavi support for rotavirus vaccina-
tion and plans to introduce vaccination in 2018. This analysis eval-
uates the impact and cost-effectiveness of rotavirus vaccination in
Bangladesh and provides estimates of the costs of the vaccination
program to help inform decision-makers in Bangladesh and inter-
national partners.
2. Materials and methods
This analysis examines the cost-effectiveness of a routine infant
rotavirus vaccination program in Bangladesh compared to no vac-
cination. We examine nationwide introduction of a two-dose rota-
virus vaccine beginning in 2017. Benefits and costs are examined
from the societal perspective over ten successive birth cohorts.
Costs and benefits are discounted at 3% per annum. All monetary
units are adjusted to 2016 USD. Key outputs of the analysis
include: deaths averted; disability adjusted life years (DALYs)
averted; cases averted; inpatient visits averted; outpatient visits
averted; informal ‘‘visits” averted; and health costs averted as a
result of rotavirus vaccination. Additional outputs include total
cost of vaccination program and cost/DALY averted.
This analysis tracks disease events and costs in ten vaccinated
cohorts over the first five years of their life. During this time, they
may or may not get rotavirus disease. If they acquire rotavirus, it
can be either non-severe or severe. In either case, treatment for
rotavirus disease can be sought as an inpatient (facility-based set-
ting) or as an outpatient (facility-based or informal setting). A
facility-based setting could be a hospital or clinic and an informal
setting could include a faith-based healer or the acquisition of oral
rehydration salts. Non-severe disease results in recovery with or
without informal or outpatient care. Severe disease results in
recovery or death with or without informal or inpatient care.
2.1. Model
This analysis uses Version 2.0 of the TRIVAC model. This Excel-
based model was developed by researchers from the London
School of Hygiene and Tropical Medicine (LSHTM) with support
from Pan American Health Organization’s (PAHO’s) ProVac Initia-
tive. The model is designed to be used at the country-level to con-
duct cost-effectiveness analyses for three vaccines: Rotavirus
vaccine, Pneumococcal conjugate vaccine, and Haemophilus
influenza type b and provides a consistent and transparent frame-
work for comparing the impact and cost-effectiveness of these vac-
cines [10]. The model has been widely used across the world to
evaluate the cost-effectiveness of these vaccines [11–16]. The
model input parameters include: demographics, burden of disease,
vaccine schedule, vaccine efficacy, vaccine coverage, vaccine costs,
health service utilization, and health service costs. More detail on
input parameters and values is included below.
2.2. Demographic data
Data on the number of live births and life expectancy at birth
were gathered from the United Nations Populations Division [17].
Infant and child mortality data in Bangladesh were taken from
the United Nations Inter-agency Group for Child Mortality Estima-
tion [18]. The annual rate of reduction in infant and child mortality
over the 2005–2015 period was used to project infant and child
mortality rates through 2026.
2.3. Disease burden
2.3.1. Incidence and severity
The incidence of rotavirus in the under-five population is esti-
mated to be 10,000 cases per 100,000 children. This value is based
on a systematic review and meta-analysis by Bilcke et al. [19]. It is
also corroborated by Zaman et al. which found an incidence of
rotavirus gastroenteritis of 9,500/100,000 person years in the con-
trol arm of a RotaTeq trial in Bangladesh and in Vietnam [8]. Platts-
Mills et al. note that 13% of all cause diarrhea episodes were severe,
and subsequent unpublished analysis indicates that 27% of rota-
virus episodes were severe in the same study [20,21]. This is a con-
servative estimate of rotavirus severity relative to other studies in
the region [8]. Severity is defined by the duration and number of
loose stools; and duration of vomiting, dehydration, and fever.
2.3.2. Mortality
There is substantial divergence in rotavirus mortality estimates
in Bangladesh. Some estimate fewer than 1000 deaths per year [3]
while others estimate over 2700 deaths per year [4]. To account for
this divergence, we examine a midpoint mortality scenario with
1850 deaths from rotavirus in children under five per annum prior
to vaccination. We also include scenarios with 1000 and 2700 rota-
virus deaths in children under five prior to vaccination. A more
extensive set of disease burden parameters is included in Table 1.
2.4. Vaccine coverage and efficacy
Vaccine coverage is high in Bangladesh. DTP1 is 97% and the
second dose is interpolated as 95.5% based on DTP3 coverage of
94% [24]. Vaccine efficacy for severe and non-severe disease in
the first year following vaccination is 48% and 45.2%, respectively.
Vaccine efficacy decreases by 36% per year.1 These values are based
on an unpublished analysis of a Rotarix trial in Bangladesh [25]. We
assume single dose efficacy is half that of the two dose course. We
exclude any indirect benefit of vaccination, i.e. herd effects.
2.5. Vaccine price and delivery cost
We model the vaccine price using Gavi’s projection of Bangla-
desh’s co-financing shares as they increase over time. Using a Gavi
price of $2.19 per dose results in a vaccine price for Bangladesh of
$0.16 in 2017 and this increases by 15% a year to $0.55 by 2026
[26,27]. We compare this to a vaccine price of $2.19 per dose, with-
out a Gavi subsidy. We assume an additional 3% and 2% of the vac-
cine cost for handling and delivery, respectively. We also assume
5% vaccine wastage.
We initially, and conservatively, estimated the delivery cost as
$0.80 per dose. This estimate is an average cost per dose delivered
across the relevant Expanded Program on Immunization (EPI) cost
categories for 2017 in the 2014–2018 cMYP [28]. Rotavirus rele-
vant expenditure categories include personnel; maintenance and
overhead; short term training; information, education, communi-
cation (IEC) and social mobilization; disease surveillance; program
management; other routine recurrent costs; vehicles; and other
capital equipment. These costs were allocated to rotavirus vaccines
and other vaccines on a per dose basis. New cold chain investments
were allocated to rotavirus vaccines and other new vaccines by
1 This is a relative decrease, not an absolute decrease.
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volume, and the cost per dose of these capital investments was
evenly distributed over ten years. Commodities, transport, cam-
paign, and shared health systems costs were excluded. Upon con-
sultation with local experts, we revised our initial estimate to
include only half of personnel costs. The rationale is that the incre-
mental labor costs associated with an additional vaccine are
expected to be much lower than the average labor cost per dose.
Using a lower, but still conservative, labor estimate yields a per
dose cost of delivery of $0.54. We explore this variable in the sen-
sitivity analysis.
2.6. Health service utilization and costs
Per Das et al., 88% of children under five receive care outside
the home for diarrhea [29]. However, the 2014 Demographic
Health Survey reports that approximately 36% of children under
five receive treatment from a facility or formal provider [30]. To
account for the population that seeks care informally and to
capture these informal costs, we differentiate cases into those
that seek formal or informal care. If 88% of children with diar-
rhea receive formal or informal care and 36% of those seeking
treatment receive formal care, this implies 41% (i.e. 0.36/0.88)
of those seeking care will receive care in a facility. The remain-
ing treatment seekers will seek care in an informal setting. This
health service utilization data is combined with incidence data
to determine the population that seeks care for rotavirus
disease.
Rotavirus cases generate costs borne by households and provi-
ders, these costs are detailed in Table 2. Households will incur
costs in the case of informal, formal outpatient, or formal inpatient
care. Providers (e.g. the government) will incur costs for formal
outpatient or formal inpatient care. We first discuss informal and
formal outpatient costs for households and providers and then pro-
ceed to discuss inpatient costs for households and providers.
Household costs associated with all informal treatment are esti-
mated from Das et al. and sum to $1.17 [31].2 Household costs asso-
ciated with formal outpatient care are estimated from the same
source and total $1.39. These informal and outpatient cost estimates
exclude lost income. Provider costs are zero in the case of informal
care and total $1.88 for formal outpatient care based on estimates
from Das et al. While the TRIVAC model differentiates between
household and provider costs, Das et al. do not make this distinction.
To avoid double counting, we allocate costs by category and allocate
them to the household or provider in an attempt to adequately rep-
resent the costs borne by each group. Estimates of provider costs
may be conservative as they are gathered from a study of household
medical expenditure. Any provider costs that are not passed on to
patients will be underestimated but would have a small impact on
results. While imperfect, our estimates are in the range of those
reported in Rheingans et al. increasing our confidence in our esti-
mates [32].
Inpatient rotavirus costs were estimated from Ahmed et al. and
total $51.21 for households and $11.41 for providers [33]. Inpatient
household costs include both direct medical costs as well as indi-
rect costs such as lost wages. All cost inputs were adjusted to
2016 USD using the period average official exchange rate and the
consumer price index [34,35].
3. Results
We present three scenarios that correspond to three distinct
mortality estimates including a low estimate, high estimate, and
a midpoint estimate [2–4]. The scenarios are detailed in Table 3
and illustrate the impact of rotavirus vaccination over ten years
beginning in 2017. All model inputs are consistent across the sce-
narios with the exception of the case fatality rate for severe dis-
ease. Variation in the case fatality rate is used to influence pre-
vaccination rotavirus mortality in the model. In each scenario we
use a vaccine price per dose that accounts for a Gavi subsidy and
increases over time from $0.16 in 2017 to $0.55 by 2026. We also
examine the full cost of the vaccine at $2.19 per dose.
With a Gavi subsidy, cost/DALY ratio’s ranged from $58/DALY
averted in the high mortality scenario to $142/DALY averted in
the low mortality scenario. Without a Gavi subsidy and a vaccine
price of $2.19 per dose, the cost/DALY ratio is substantially higher,
ranging from $615/DALY averted in the high mortality scenario to
$1514/DALY averted in the low mortality scenario. Cost per death
and cases averted are also contained in the table. In each scenario,
Table 1
Input parameters for estimating disease burden.
Parameter Estimate Source/s
Annual incidence per 100,000 aged 1–59months:
Rotavirus (non-severe) cases 7300 Assumption, based on
[19–21]
Rotavirus (severe) cases 2700 Assumption, based on
[19–21]
Rotavirus deaths (low, mid, high
estimates)a
1000,1850,
2700
[2,3]
Disability weight for DALY calculations
Rotavirus (non-severe) cases 0.188 Data from
supplementary tables in
[22]
Rotavirus (severe) cases 0.247 Data from
supplementary tables in
[22]
Mean duration of illness (in days)
Rotavirus (non-severe) cases 6 Assumption
Rotavirus (severe) cases 6 Assumption
Age distribution of disease cases and deaths
<3 months: 0.5% [23]
3–5 months: 6.1% [23]
6–8 months: 21.8% [23]
9–11 months: 22.7% [23]
12–23 months: 46.0% [23]
24–35 months: 2.7% [23]
36–47 months: 0.1% [23]
48–59 months: 0.0% [23]
a These estimates were calculated using the case fatality ratio. These calculations
are aligned with estimates from the IHME, CDC, and WHO as referenced in text.
Table 2
Input parameters for estimating health service costs (all costs are presented in 2016
USD).
Parameter Estimate Source/s
Government cost per visit
Non-severe rotavirus cases
Facility (outpatient) $1.88 [31]
Severe rotavirus cases
Facility (inpatient) $11.41 [33]
Household cost per visit
Non-severe rotavirus cases
Informal $1.17 [31]
Facility (outpatient) $1.39 [31]
Severe rotavirus cases
Informal $1.17 [31]
Facility (inpatient) $51.21 [33]
2 Median costs before attending a facility are a proxy for the cost of informal care.
Also note, Das et al. do not distinguish costs by disease severity. We utilize their
median cost estimates so costs do not reflect inpatient care.
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rotavirus vaccination will avert thousands of deaths, DALYs, mil-
lions of cases and visits, as well as millions in health costs while
also incurring millions of vaccination program costs. To put gov-
ernment costs in context, the net cost of the vaccine program in
2017 (with annualized introduction costs) is approximately one
and a half percent of EPI program expenditure [28].
In addition to the three mortality scenarios presented above, we
conducted a one way sensitivity analysis of the midpoint mortality
scenario (incorporating the Gavi vaccine subsidy) to understand
how variation in key input variables would impact results. Table 4
contains the base, low, and high data inputs. The impact these
varying inputs have on the results is then represented in the tor-
nado diagram (Fig. 1) that follows.
The delivery cost per dose, the share of severe cases, and inpa-
tient treatment costs have the largest impact on the results, given
the range of inputs varied here (Fig. 1). At the low end of the deliv-
ery cost range and the high end of the severe cases and inpatient
treatment cost range, rotavirus vaccination is cost saving. In no
case does the cost/DALY exceed $275.
4. Discussion
Rotavirus vaccination would substantially reduce mortality, ill-
ness, and costs (including out of pocket costs) associated with rota-
virus disease, and this is accounting only for the direct effects so
these estimates are conservative. By almost any measure, rotavirus
vaccination is highly cost-effective with a Gavi subsidy. Without a
Gavi subsidy, the cost-effectiveness ratio is of the same magnitude
Fig. 1. One-way sensitivity analysis of cost per DALY over 10 Years.
Table 3
Key model outputs by scenario.
Midpoint
mortality
scenario
Low
mortality
scenario
(IHME)
High
mortality
scenario
(WHO/CDC)
Baseline rotavirus deaths
(2017)
1850 980 2700
Baseline rotavirus admissions
(2017)
160,000 160,000 160,000
Baseline rotavirus cases (2017) 1.5 million 1.5 million 1.5 million
Model output with vaccination over 10 years, benefits and costs
discounted
Deaths averted 3900 2100 5800
DALYs averted 130,000 74,000 183,000
Cases averted 3.9 million 3.9 million 3.9 million
Inpatient visits averted 450,000 450,000 450,000
Outpatient visits averted 1.2 million 1.2 million 1.2 million
Informal ‘‘visits” averted 1.7 million 1.7 million 1.7 million
Health costs averted
(government/societal)
$7.0/$33.7
million
$7.0/$33.7
million
$7.0/$33.7
million
Cost of vaccination program
with and w/o Gavi subsidy
(excludes health savings)
$44.3/
$146.3
million
$44.3/
$146.3
million
$44.3/$146.3
million
Cost/DALY averted with and w/
o Gavi subsidy
$82/$871 $142/$1514 $58/$615
Cost/death averted with and w/
o Gavi subsidy
$2689/
$28,593
$5098/
$54,207
$1840/
$19,563
Cost/case averted with and w/o
Gavi subsidy
$3/$29 $3/$29 $3/$29
Table 4
Sensitivity analysis of midpoint mortality scenario.a
Input variable Base input
value
Low input
value
High input
value
Incidence (per 100,000) 10,000 8000 12,000
Severe cases 27% 17% 37%
Vaccine effectiveness, severe disease 48% 38% 58%
Vaccine wastage 5% 0% 20%
Annual decrease in effectiveness 36% 16% 56%
Delivery cost per dose $0.54 $0.25 $1.00
Average inpatient treatment costs
(provider + household)
$62.62 $31.31 $125.24
Average outpatient treatment costs
(provider + household)
$3.27 $1.64 $6.54
Average informal treatment costs $1.17 $0.59 $2.34
Duration of illness (non-severe and
severe)
6 days 2 days 10 days
a Note that the variation in input values relative to the base input is not uniform.
Also note that an increase in an input value may cause the cost-effectiveness ratio
to decrease while an increase in another input value may cause an increase in the
cost-effectiveness ratio.
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as Bangladesh’s per capita income. Per capita income thresholds
have often been used as a measure of cost-effectiveness, but there
are limitations to that approach [36]. Ideally, cost-effectiveness
should be included as an input into a transparent decision-
making process alongside other considerations like budget impact,
sustainability, feasibility, and equity [37]. Some countries have
developed their own thresholds over time, and the authors of this
work see value in a country specific approach [37]. However, no
such threshold exists in Bangladesh. If per capita income thresh-
olds were applied using Bangladesh’s 2015 per capita GNI of
$1190, rotavirus vaccination would be highly cost-effective in five
of six scenarios, and cost-effective in the ‘‘low mortality, no Gavi
subsidy” scenario [38]. This result is consistent with results from
other low resource countries with a high rotavirus burden [39].
Importantly, this analysis also demonstrates that rotavirus vacci-
nation can be cost-effective outside of high mortality contexts
and absent Gavi support. This supports the argument that other
countries in Asia may wish to consider rotavirus vaccination as a
cost-effective intervention even in the absence of a high mortality
burden or Gavi support. These results suggest that factors other
than mortality (e.g., the cost of care that can be averted) will be
an increasingly important rationale for introducing rotavirus vacci-
nation for the countries in the region that have yet to introduce
vaccination. In Bangladesh, the sensitivity analysis shows that
averted inpatient expenditures are important. This includes out
of pocket expenditures which are estimated to be over 60% of Ban-
gladesh’s total health spending [40].
This study is a collaboration between international researchers,
local policy makers, and vaccine program staff. Many of the data
inputs were locally acquired and complemented by internationally
validated estimates. As such, this study benefited from international
rotavirus expertise as well as the strong evidence base developed in
Bangladesh.One limitationof this analysis is the lackof detaileddata
on themarginal cost of vaccine delivery.However, engagementwith
local partners allowed us to coalesce around delivery cost estimates
that made use of available data and also corresponded to local per-
spectives.While local data and expertise strengthened this analysis,
it is important to note that this is a prospective analysis meaning
that these are estimatesof futurebenefits and costs rather thanmea-
surable retrospective outcomes. TheTRIVACmodel is a decision sup-
port tool that was critical in completing this analysis and provided a
framework for country-level engagement regarding both data
inputs and results. TRIVAC also provides an avenue to build local
health economic capacity, not just for those engaged in data collec-
tion and modelling, but also decision-making.
Bangladesh recently made the decision to introduce rotavirus
vaccination and has applied for Gavi support. This analysis played
a role in informing international partners and local decision mak-
ers of the benefits and costs of rotavirus vaccination in Bangladesh.
Cost-effectiveness analyses, alongside budget impact analyses, are
playing an increasingly important role in guiding local and interna-
tional decision-making. Given the strong results presented here, it
is likely that other countries in the region may also find rotavirus
vaccination to be both cost-effective and affordable.
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